Adamgammadex sodium - Hangzhou Adamerck
Alternative Names: Aom-0319Latest Information Update: 01 Sep 2023
At a glance
- Originator Hangzhou Adamerck
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Brain injuries
Most Recent Events
- 15 Dec 2022 Phase-I clinical trials in Brain injuries (In volunteers) in Australia (IV) (NCT05555758)
- 27 Sep 2022 Amckaus plans a phase I trial for Healthy volunteers in Australia in November 2022 (NCT05555758)
- 23 Jun 2022 Early research in Brain injuries in China, Prior to June 2022 (Hangzhou Adamerck pipeline, June 2022)